OFI Invest Asset Management Grows Position in Becton, Dickinson and Company $BDX

OFI Invest Asset Management raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 2,808.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 154,984 shares of the medical instruments supplier’s stock after purchasing an additional 149,656 shares during the quarter. OFI Invest Asset Management owned approximately 0.05% of Becton, Dickinson and Company worth $30,078,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Becton, Dickinson and Company by 0.5% during the third quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock valued at $6,074,750,000 after purchasing an additional 147,041 shares during the last quarter. State Street Corp lifted its holdings in Becton, Dickinson and Company by 3.4% during the third quarter. State Street Corp now owns 13,872,395 shares of the medical instruments supplier’s stock valued at $2,596,496,000 after purchasing an additional 459,219 shares during the last quarter. First Eagle Investment Management LLC increased its position in shares of Becton, Dickinson and Company by 13.8% during the third quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier’s stock valued at $1,870,653,000 after buying an additional 1,208,218 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Becton, Dickinson and Company by 7.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 9,150,584 shares of the medical instruments supplier’s stock valued at $1,712,715,000 after acquiring an additional 636,138 shares during the period. Finally, Wellington Management Group LLP boosted its position in shares of Becton, Dickinson and Company by 9,056.3% in the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after acquiring an additional 5,174,944 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the sale, the director owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 2,713 shares of company stock valued at $536,881. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Trading Up 1.3%

Shares of Becton, Dickinson and Company stock opened at $156.98 on Thursday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The firm has a market cap of $44.70 billion, a PE ratio of 25.61, a PEG ratio of 11.20 and a beta of 0.29. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The company has a 50 day simple moving average of $172.86 and a two-hundred day simple moving average of $185.81.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business had revenue of $4.49 billion during the quarter, compared to analyst estimates of $5.15 billion. During the same period in the previous year, the business posted $3.43 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has approved a share repurchase plan on Tuesday, January 27th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th were given a dividend of $1.05 per share. The ex-dividend date was Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.7%. Becton, Dickinson and Company’s payout ratio is presently 68.52%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on BDX shares. JPMorgan Chase & Co. cut their price objective on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Bank of America raised their price objective on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research report on Monday, January 5th. Jefferies Financial Group cut their price objective on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Tuesday, February 10th. Barclays started coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 price objective for the company. Finally, Wells Fargo & Company cut their price objective on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 10th. Six analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $191.62.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.